aDivision of Nephrology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
bINSERM U1083, CNRS UMR 6214, Centre Hospitalo-Universitaire d’Angers, Université d’Angers, Angers
cFaculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité
dINSERM U970, Cardiovascular Epidemiology and Sudden Cardiac Death, Paris, France
eInternal Medicine Department, Center for the Research and Treatment of Arterial Hypertension and Cardiovascular Risk, Hospital Senhora da Oliveira
fLife and Health Science Research Institute (ICVS), School of Medicine, University of Minho
gICVS/3B's – PT Government Associate Laboratory, Guimarães, Portugal
hDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK
iCardiovascular Prevention & Research Unit, Department of Pathophysiology Medical School, National and Kapodistrian University of Athens, Athens, Greece
jINSERM U970, Paris, France
kInstitute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
lDepartment of Medicine, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
mDepartment of Biomedical Engineering, School of Engineering & Applied Science, Yale University, New Haven, Connecticut, USA
nDepartment of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands
oU.F.R. d’odontologie, Université Paris Diderot, Hôpital Rothschild AP-HP, Paris, France
pUniversity of Athens Medical School, Athens, Greece
qDepartment of Pharmacology, HEGP, AP-HP, Paris, France
Correspondence to Luca Zanoli, MD, PhD, FASN, Department of Clinical and Experimental Medicine, Policlinico Universitario di Catania, University of Catania, Via Santa Sofia 78, 95123 Catania, Italy. Tel: +39 3474574122; fax: +39 0953782376; e-mail: [email protected]
Abbreviations: AII, angiotensin II; AIX, augmentation index; BP, blood pressure; ChAT, choline acetyltransferase; CHD, coronary heart disease; CRP, mediator C-reactive protein; CVD, cardiovascular diseases; DAMP, damage-associated molecular pattern; FMD, flow-mediated dilatation; Foxp3; forkhead box P3; IBD; inflammatory bowel disease; ICAM; intercellular adhesion molecule; IMT; intima–media thickness; MMP, matrix metalloproteinase; NLRP3, NOD-like receptor family, pyrin domain containing 3; NO, nitric oxide; NOX, adenine dinucleotide phosphate oxidase; Nrf-2, nuclear factor erythroid 2-related factor 2; PSV, primary systemic vasculitides; PWV, pulse wave velocity; ROS, radical oxygen species; SLE, systemic lupus erythematosus; SPM, specialized proresolving mediator; SSc, systemic sclerosis; TEM
, effector memory cells; TLR, Toll-like receptor; VSMC, vascular smooth muscle cells
Received 4 October, 2019
Revised 10 April, 2020
Accepted 18 April, 2020
